You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Alk-positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Iruplinalkib in Treatment of ALK-Positive Non-Small Cell Lung

Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Aug 8, 2023

ALK Positive NSCLC Trial in Guangzhou (Loratinib)

Recruiting
  • ALK Positive Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial Perople's Hospital
Oct 19, 2023

NSCLC(NSCLC) Trial in Jinan (WX-0593 Tablets)

Not yet recruiting
  • Non-Small Cell Lung Cancer(NSCLC)
  • WX-0593 Tablets
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Mar 1, 2023

ALK-positive NSCLC Trial in Shanghai (Alkotinib Capsules)

Recruiting
  • ALK-positive Non-small Cell Lung Cancer
  • Alkotinib Capsules
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Nov 28, 2022

Non-small-cell Lung Carcinoma Trial in Beijing (SY-3505)

Recruiting
  • Non-small-cell Lung Carcinoma
  • Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
May 11, 2023

NSCLC Trial in Shanghai (WX-0593)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, China
    Shanghai Jiao Tong University Chest Hospital
Mar 24, 2023

ALK-positive NSCLC Trial in Jilin (XZP-3621)

Not yet recruiting
  • ALK-positive NSCLC
  • Jilin, Chang Chun, China
    Jilin Province Cancer Hospital
Jul 29, 2022

NSCLC Trial in Davis, San Francisco (Ceritinib, Trametinib)

Terminated
  • Non-small Cell Lung Cancer
  • Davis, California
  • +1 more
Dec 22, 2022

ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

Completed
Has Results
  • ALK-positive NSCLC
  • Sollentuna, Sweden
    Pfizer Innovations AB
Mar 14, 2022

Non Small Cell Lung Cancer Trial in Beijing (Ensartinib)

Recruiting
  • Non Small Cell Lung Cancer
  • Beijing, Beijing, China
  • +1 more
Aug 17, 2022

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • Beijing, Beijing, China
    Department of Respiratory and Critical Care Medicine, Peking Uni
Aug 10, 2022

ALK Positive Tumors Trial (ceritinib)

No longer available
  • ALK Positive Tumors
  • (no location specified)
Nov 30, 2021

ALK-positive NSCLC Trial in Dallas (Ceritinib, Stereotactic ablative body radiation)

Terminated
Has Results
  • ALK-positive Non-small Cell Lung Cancer
  • Dallas, Texas
    UT Southwestern Medical Center
Jan 31, 2023

Anaplastic Lymphoma Kinase-Positive Non-small Cell Lung Cancer

Active, not recruiting
  • Non-Small-Cell Lung Carcinoma
  • New York, New York
    Pfizer Inc
Apr 12, 2022

Advanced NSCLC Trial in India (Lorlatinib)

Completed
  • Advanced Non-Small Cell Lung Cancer
  • New Delhi, Delhi, India
  • +11 more
Sep 13, 2022

NSCLC Trial in Tianjin (Ensartinib, Placebo)

Recruiting
  • Non-small Cell Lung Cancer
  • Tianjin, China
    TianJin Medical University Cancer Institute & Hospital
Jul 13, 2022

Non Small Cell Lung Cancer Trial in Goyang-si (Brigatinib)

Recruiting
  • Non Small Cell Lung Cancer
  • Goyang-si, Gyeonggi-do, Korea, Republic of
    National Cancer Center
Apr 4, 2022

Non Small Cell Lung Cancer Trial (TGRX-326, Crizotinib)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • (no location specified)
Oct 8, 2023

Ensatinib in alK-positive Patients Undergoing Initial Treatment

Recruiting
  • ALK Positive
  • +2 more
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Nov 16, 2021

Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma

Active, not recruiting
  • ALK-Positive Anaplastic Large Cell Lymphoma
  • RNAseq
  • Toulouse, France
    IUCT-Oncopole University Hospital
Jul 3, 2023

NSCLC Trial in Beijing (SY-3505)

Recruiting
  • Non-small Cell Lung Cancer
  • Beijing, Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Mar 17, 2022

Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor Trial in Utrecht

Recruiting
  • Anaplastic Large Cell Lymphoma, ALK-Positive
  • +2 more
  • Paris, France
  • +1 more
Sep 27, 2022

NSCLC Stage IV, ALK Fusion Protein Expression Trial (Peptide vaccine)

Not yet recruiting
  • NSCLC Stage IV
  • ALK Fusion Protein Expression
  • Peptide vaccine
  • (no location specified)
Jul 21, 2023

NSCLC Trial in Shijiazhuang (Ensartinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Shijiazhuang, Hebei, China
    Jun Feng Liu
Feb 6, 2022

ALK Fusion Protein Expression, Adjuvant Therapy, NSCLC Trial (Ensatinib, chemo)

Not yet recruiting
  • ALK Fusion Protein Expression
  • +2 more
  • (no location specified)
Jan 10, 2022